Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 9, 2013, Pages 1129-1137

  Sahara, S ^a   Sugimoto, M ^a   Uotani, T ^a   Ichikawa, H ^a   Yamade, M ^a   Iwaizumi, M ^a   Yamada, T ^a   Osawa, S ^a   Sugimoto, K ^a   Umemura, K ^a   Miyajima, H ^a   Furuta, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE;

ACID SECRETION; ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2C19 GENE; DRUG METABOLISM; ESOPHAGEAL PH MONITORING; FEMALE; GENOTYPE; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; ESOMEPRAZOLE; FEMALE; GASTRIC ACID; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; JAPAN; LANSOPRAZOLE; MALE; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; RABEPRAZOLE; YOUNG ADULT;

EID: 84885087548     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12492     Document Type: Article

References (50)

1. Walsh JH, Peterson WL,. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. Furuta T, Sagehashi Y, Shirai N, et al,. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-73. (Pubitemid 40824749)
3. Furuta T, Shirai N, Watanabe F, et al,. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60. (Pubitemid 35178870)
4. Sugimoto M, Furuta T, Shirai N, et al,. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-23. (Pubitemid 47196333)
5. Ishizaki T, Horai Y,. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl 3): 27-36. (Pubitemid 29389409)
6. Horai Y, Kimura M, Furuie H, et al,. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793-803. (Pubitemid 32500425)
7. Shirai N, Furuta T, Moriyama Y, et al,. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37. (Pubitemid 34014349)
8. Sugimoto M, Furuta T, Shirai N, et al,. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301. (Pubitemid 39313119)
9. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L,. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63. (Pubitemid 26011441)
10. Kubota T, Chiba K, Ishizaki T,. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6. (Pubitemid 27025913)
11. Sim SC, Risinger C, Dahl ML, et al,. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-13. (Pubitemid 43069582)
12. Sugimoto K, Uno T, Yamazaki H, Tateishi T,. Limited frequency of the CYP2C1917 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65: 437-9. (Pubitemid 351316919)
13. Furuta T, Ohashi K, Kosuge K, et al,. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-61. (Pubitemid 29237329)
14. Furuta T, Shirai N, Takashima M, et al,. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341-8. (Pubitemid 32537408)
15. Sugimoto M, Furuta T, Shirai N, et al,. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77: 302-11. (Pubitemid 40470386)
16. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L,. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-72. (Pubitemid 30612617)
17. Hassan-Alin M, Andersson T, Niazi M, Rohss K,. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005; 60: 779-84. (Pubitemid 40394571)
18. Andersson T, Rohss K, Bredberg E, Hassan-Alin M,. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9. (Pubitemid 32912398)
19. Peterson WL,. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 (Suppl 1): 21-5.
20. Sugimoto M, Shirai N, Nishino M, et al,. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36: 627-34.
21. Furuta T, Shirai N, Takashima M, et al,. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-68. (Pubitemid 32225416)
22. Zendehdel N, Biramijamal F, Hossein-Nezhad A, Sarie H, Doughaiemoghaddam M, Pourshams A,. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 2010; 13: 406-12.
23. Kawamura M, Ohara S, Koike T, et al,. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73. (Pubitemid 36459609)
24. Kawamura M, Ohara S, Koike T, et al,. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22: 222-6. (Pubitemid 46181352)
25. Saitoh T, Otsuka H, Kawasaki T, et al,. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology 2009; 56: 703-6.
26. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH,. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl 1): 59-67.
27. Labenz J, Stolte M, Blum AL, et al,. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43.
28. Furuta T, Shirai N, Kodaira M, et al,. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-8. (Pubitemid 46452299)
29. Shirai N, Furuta T, Xiao F, et al,. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16: 837-46. (Pubitemid 34407534)
30. Bardhan K, Bayerdorffer E,. Veldhuyzen Van Zanten SJ, Lind T, Megraud F, Delchier JC, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000; 5: 196-201. (Pubitemid 34948000)
31. McColl KE, Kennerley P,. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 2002; 34: 461-7. (Pubitemid 34830685)
32. Rohss K, Wilder-Smith C, Naucler E, Jansson L,. Esomeprazole 20 mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004; 24: 1-7. (Pubitemid 38197747)
33. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y,. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19: 113-22. (Pubitemid 38125644)
34. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO,. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009; 65: 55-64.
35. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T,. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484-92. (Pubitemid 33135329)
36. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr,. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-9. (Pubitemid 19265874)
37. Goddard AF, Jessa MJ, Barrett DA, et al,. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-67. (Pubitemid 26256723)
38. Scott D, Weeks D, Melchers K, Sachs G,. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl 1): S56-60. (Pubitemid 28338114)
39. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S,. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9. (Pubitemid 34664773)
40. Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL,. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11: 3091-8. (Pubitemid 40790669)
41. Adachi K, Hashimoto T, Hamamoto N, et al,. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003; 18: 1392-8. (Pubitemid 38045853)
42. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L,. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 445-54. (Pubitemid 34214523)
43. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL,. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85. (Pubitemid 34214527)
44. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810. (Pubitemid 27240763)
45. van Pinxteren B, Numans ME, Bonis PA, Lau J,. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; (3): CD002095.
46. Kinoshita Y, Hongo M,. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol 2012; 107: 522-30.
47. Bate CM, Green JR, Axon AT, et al,. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755-63. (Pubitemid 27376365)
48. Fass R,. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (3 Suppl): S2-7. (Pubitemid 36348509)
49. Uemura N, Inokuchi H, Serizawa H, et al,. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43: 670-8.
50. Hayato S, Hasegawa S, Hojo S, et al,. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol 2012; 68: 579-88.